NEWS
Enantia enhances its Solid-State Capabilities with the acquisition of the Empyrean X-Ray Diffractometer
Enantia is pleased to announce the acquisition of the Empyrean X-ray diffractometer by Malvern Panalytical, further...
INVACO Acquires ENANTIA to Drive Expansion and Growth in Specialized CRO Services
Enantia, a leading contract research organization (CRO) with over 20 years of experience in chemistry services, has...
Enantia is proud to announce the inclusion of continuous flow chemistry to our Drug Discovery and API Development services
Enantia is proud to offer flow chemistry as part of our services in medicinal chemistry and CMC development. Flow...
Enantia has renewed the Credit d’Impôt Recherche (CIR) from the French authorities
The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt...
Enantia at ALBA Synchrotron workshop
Next June 17th the ALBA Synchrotron will host the workshop: “ALBA Synchrotron Applications for the Pharmaceutical...
Enantia extends its service portfolio to HPAPIs
High Potency Active Pharmaceutical Ingredients, also called Highly Potent API (HPAPI), exert their activity at a very...
New cocrystal discovered at Enantia approved by the FDA
On October 15th, 2021, the FDA approved Seglentis for acute pain treatment in adults in the United States. This...